Anti-oxidant properties of high-density lipoprotein and atherosclerosis
- PMID: 20374263
- PMCID: PMC3010184
- DOI: 10.1111/j.1440-1681.2010.05380.x
Anti-oxidant properties of high-density lipoprotein and atherosclerosis
Abstract
1. High-density lipoprotein (HDL) is one of the major carriers of cholesterol in the blood. It attracts particular attention because, in contrast with other lipoproteins, many physiological functions of HDL influence the cardiovascular system in favourable ways unless HDL is modified pathologically. 2. The best known function of HDL is the capacity to promote cellular cholesterol efflux from peripheral cells and deliver cholesterol to the liver for excretion, thereby playing a key role in reverse cholesterol transport. The functions of HDL that have recently attracted attention include anti-inflammatory and anti-oxidant activities. High anti-oxidant and anti-inflammatory activities of HDL are associated with protection from cardiovascular disease. 3. Atheroprotective activities, as well as a functional deficiency of HDL, ultimately depend on the protein and lipid composition of HDL. Conversely, these activities are compromised in many pathological states associated with inflammation. 4. The focus of the present review is on the anti-oxidant and anti-inflammatory functions of HDL and its individual components in relation to protection from atherosclerosis.
Similar articles
-
The antioxidant properties of high-density lipoproteins in atherosclerosis.Panminerva Med. 2012 Jun;54(2):83-90. Panminerva Med. 2012. PMID: 22525563 Review.
-
High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis.Curr Pharm Des. 2010 May;16(13):1445-67. doi: 10.2174/138161210791051022. Curr Pharm Des. 2010. PMID: 20199377 Review.
-
High-density lipoproteins, inflammation and oxidative stress.Clin Sci (Lond). 2009 Jan;116(2):87-98. doi: 10.1042/CS20080106. Clin Sci (Lond). 2009. PMID: 19076062 Review.
-
Laboratory investigation of dysfunctional HDL.Chem Phys Lipids. 2012 Jan;165(1):32-7. doi: 10.1016/j.chemphyslip.2011.10.005. Epub 2011 Oct 25. Chem Phys Lipids. 2012. PMID: 22064068 Review.
-
Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.J Ren Nutr. 2010 Sep;20(5 Suppl):S35-43. doi: 10.1053/j.jrn.2010.05.010. J Ren Nutr. 2010. PMID: 20797569 Review.
Cited by
-
Structural Characteristics of PON1 with Leu55Met and Gln192Arg Variants Influencing Oxidative-Stress-Related Diseases: An Integrated Molecular Modeling and Dynamics Study.Medicina (Kaunas). 2023 Nov 22;59(12):2060. doi: 10.3390/medicina59122060. Medicina (Kaunas). 2023. PMID: 38138163 Free PMC article.
-
Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype.J Am Heart Assoc. 2013 Apr 4;2(2):e000063. doi: 10.1161/JAHA.113.000063. J Am Heart Assoc. 2013. PMID: 23557750 Free PMC article.
-
Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study.BMC Psychiatry. 2016 Aug 25;16(1):299. doi: 10.1186/s12888-016-1006-3. BMC Psychiatry. 2016. PMID: 27562545 Free PMC article.
-
Altered inflammation, paraoxonase-1 activity and HDL physicochemical properties in obese humans with and without Prader-Willi syndrome.Dis Model Mech. 2012 Sep;5(5):698-705. doi: 10.1242/dmm.009209. Epub 2012 Jul 19. Dis Model Mech. 2012. PMID: 22822045 Free PMC article.
-
HDL and endothelial protection.Br J Pharmacol. 2013 Jun;169(3):493-511. doi: 10.1111/bph.12174. Br J Pharmacol. 2013. PMID: 23488589 Free PMC article. Review.
References
-
- Kontush A, Chapman MJ. Functionally defective high-density lipoprotein. A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342–74. - PubMed
-
- Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: How much versus how good. J Atheroscler Thromb. 2008;15:52–62. - PubMed
-
- Heller M, Stalder D, Schlappritzi E, Hayn G, Matter U, Haeberli A. Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics. 2005;5:2619–30. - PubMed
-
- Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II. Mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005;5:1431–45. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous